The SEC alleges that the company violated the Foreign Corrupt Practices Act, the federal anti-corruption law that bars U.S. corporations and citizens from bribing government officials abroad.And in related activity, the SEC accused Alexion's subsidiaries in Colombia and Brazil of failure to keep accurate documentation of payments directed to patient advocacy organizations.